These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34326946)

  • 1. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor.
    Marinkovic-Radosevic J; Cigrovski Berkovic M; Kruezi E; Bilic-Curcic I; Mrzljak A
    World J Diabetes; 2021 Jul; 12(7):932-938. PubMed ID: 34326946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 2 Diabetes Mellitus in Patients With Polycystic Ovary Syndrome.
    Agrawal A; Dave A; Jaiswal A
    Cureus; 2023 Oct; 15(10):e46859. PubMed ID: 37954695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases.
    Sanz-Cánovas J; Ricci M; Cobos-Palacios L; López-Sampalo A; Hernández-Negrín H; Vázquez-Márquez M; Mancebo-Sevilla JJ; Álvarez-Recio E; López-Carmona MD; Pérez-Velasco MÁ; Pérez-Belmonte LM; Gómez-Huelgas R; Bernal-López MR
    Rev Cardiovasc Med; 2023 Feb; 24(2):36. PubMed ID: 39077405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproductive risk factors across the female lifecourse and later metabolic health.
    Nichols AR; Chavarro JE; Oken E
    Cell Metab; 2024 Feb; 36(2):240-262. PubMed ID: 38280383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment pathways traversed by polycystic ovary syndrome (PCOS) patients: A mixed-method study.
    Kaur I; Suri V; Rana SV; Singh A
    PLoS One; 2021; 16(8):e0255830. PubMed ID: 34370764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na
    Trum M; Riechel J; Wagner S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD.
    Ala M
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34343274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.
    Dunaif A
    Endocr Rev; 1997 Dec; 18(6):774-800. PubMed ID: 9408743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives.
    Reed J; Bain S; Kanamarlapudi V
    Diabetes Metab Syndr Obes; 2021; 14():3567-3602. PubMed ID: 34413662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenetic analysis of polycystic ovary syndrome from the perspective of omics.
    Pei CZ; Jin L; Baek KH
    Biomed Pharmacother; 2021 Oct; 142():112031. PubMed ID: 34411918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: A meta-analysis and systematic review.
    Liu Y; Shao Y; Xie J; Chen L; Zhu G
    Medicine (Baltimore); 2021 Aug; 100(31):e26622. PubMed ID: 34397797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nutrition Strategy and Life Style in Polycystic Ovary Syndrome-Narrative Review.
    Szczuko M; Kikut J; Szczuko U; Szydłowska I; Nawrocka-Rutkowska J; Ziętek M; Verbanac D; Saso L
    Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease.
    Del Vecchio L; Beretta A; Jovane C; Peiti S; Genovesi S
    Drugs; 2021 Sep; 81(13):1491-1511. PubMed ID: 34363606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics.
    Singh S; Pal N; Shubham S; Sarma DK; Verma V; Marotta F; Kumar M
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS).
    Siddiqui S; Mateen S; Ahmad R; Moin S
    J Assist Reprod Genet; 2022 Nov; 39(11):2439-2473. PubMed ID: 36190593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment.
    Parker J; O'Brien C; Hawrelak J; Gersh FL
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial.
    Cai M; Shao X; Xing F; Zhang Y; Gao X; Zeng Q; Dilimulati D; Qu S; Zhang M
    Diabetes Obes Metab; 2022 Feb; 24(2):312-320. PubMed ID: 34726324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on polycystic ovary syndrome.
    Kim JJ
    Clin Exp Reprod Med; 2021 Sep; 48(3):194-197. PubMed ID: 34488284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease.
    Pokharel A; Kc S; Thapa P; Karki N; Shrestha R; Jaishi B; Paudel MS
    Cureus; 2021 Jul; 13(7):e16687. PubMed ID: 34466320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.
    Ge JJ; Wang DJ; Song W; Shen SM; Ge WH
    J Endocrinol Invest; 2022 Feb; 45(2):261-273. PubMed ID: 34455568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.